Furthermore, a recent study was undertaken to evaluate concordance between local and central laboratory testing for HER2 in breast cancer specimens from the North Central Cancer Treatment Group, N9831 Intergroup Adjuvant Trial. Here, ERBB2 is linked to breast carcinoma.